🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

O GBOT apoia o Congresso da Aliança Brasileira Contra o Câncer de Pulmão SBOC Soc. Bras. Patologia Sociedade Brasileira de Pneumologia e Tisiologia SBCT

PD-L1 & outcomes from consolidation durvalumab after chemoradiation for stage III NSCLC in Netherlands Cancer Registry Clinical Lung Cancer. From 2017 to 2021, use of PACIFIC increased from 2% to 62%. 4y OS 67% for PDL1 high, 46% for low, 51% for negative. clinical-lung-cancer.com/article/S1525-…

Muitas pessoas associam o câncer de pulmão ao tabagismo, mas não fumantes também estão em risco. Fatores como exposição ao gás radônio, fumo passivo, poluição do ar, e certos riscos ocupacionais podem contribuir para o desenvolvimento da doença. #agostobranco

It was our honor to host today our Brazilian colleagues in clinic - with a great Boston Italian lunch.

Clique no link gbot.med.br e confira o estudo completo da Dra. Flávia Amaral Duarte.

Randomized phase II RAMOSE trial Journal of Clinical Oncology: 1L osimertinib +/- ramucirumab in #EGFR NSCLC. In 139 pts, addition of ramucirumab increased PFS: 24.8m vs 15.6m (HR 0.55), seen across subgroups. OS immature. Xiuning Le MD PhD Elaine Shum Chul Kim et al. ascopubs.org/doi/10.1200/JC…

Excited to share our new study nature. Very grateful for the support of our collaborators, pharma and biotech partners and members of the Skoulidis and Heymach labs. Special thanks to star fellow haniel.araujo and Minh Truong Do. Thankful to our patients. MD Anderson Cancer Center

📊 Tansição epidemiológica em andamento no 🇧🇷: 🔸️5570 municípios 🔹️ 2000-2019: ☠️ por câncer > doenças cardiovasculares (DCV) em 13% dos municípios vs. 7% em 2000. 🎯 ☠️ por 🦀 ⬆️ 3,8811 por 100.000 🧍‍♂️🧍‍♀️🧍/ano em relação à ☠️ por DCV ⚠️ ⬆️ de ☠️ por 🦀 vs DCV em áreas>>💰.

Em entrevista para a Revista Oeste, destaquei como a decisão do STF sobre medicamentos de alto custo é extremamente prejudicial e representa um retrocesso. Também falei sobre o projeto de lei complementar 168/24 que apresentei para reduzir o impacto dessa decisão para os

The changing treatment landscape of EGFR-mutant non-small-cell lung cancer 💥Excellent review👇 nature.com/articles/s4157…

In pts with #EGFR #NSCLC, what is the value of continuing osimertinib with platinum-pemetrexed after progression vs stopping osimertinib & switching to platinum pemetrexed? I’m proud to present our multi-center, retrospective, international series published in Everyday Health 🧵

🫁 Updated of ICIs NSCLC 5 year follow up data 🫁 🌟 Clinical trials added at this time 📌 EMPOWER-Lung1 📌 POSEIDON #LCSM #NSCLC #ICI

Inspired by my good friend and slide master Jordi Remon - sharing these updated summary slides for 1L and post-progression treatment options for advanced stage EGFR-mutated NSCLC. Might be outdated soon but hopefully not before 2025 😬 OncoAlert

Stephanie Saw Jordi Remon OncoAlert Excelent! Thank you! Christmas gift, LOL!

🔈Manejo prático de eventos adversos associados a Tarlatamabe p/ pcts com câncer de 🫁 de pequenas células: - Aborda os principais EA e timing, como síndrome de liberação de citocinas e ICANS. - Estratégias p/ mitigar o risco. - Manejo de acordo com grau de severidade. Must read!

Great day for lung cancer care! Addition of just 3 cycles of nivolumab immunotherapy to standard neoadjuvant chemo leads to improved overall survival for surgically resectable lung cancer! #LCSM

Update do CheckMate 816 - press release: adição de nivolumabe à QT neoadjuvante para CPCNP ressecável melhora SG - o estudo já havia sido positivo para SLE e pCR. Precisamos de IO após a cirurgia? Vamos reacender o 🔥 da discussão! news.bms.com/news/corporate…

Zongertinib in #HER2 NSCLC simultaneous publication NEJM with #AACR25 presentation by Dr. John Heymach. In previously treated HER2 TKD mt NSCLC, RR 71%, duration of response 14.1m, mPFS 12.4m. G3 AEs in only 17% - diarrhea in 56% of pts but only 1 single case of G3 or higher.

Telisotuzumab vedotin is now U.S. FDA approved in previously treated c-Met overexpressing mNSCLC, PhII #LUMINOSITY : - ORR: 28.6% + mOS 14.5mos  - ORR 34.6% + mOS 14.6mos in cMET high - ORR 22.9% + mOS 14.2mos in cMET intm. - AEs: Neuropathy, edema, fatigue #lcsm #OncTwitter

Retrospective study of neoadjuvant immunotherapy for 112 pts with stage III borderline resectable NSCLC JAMA Oncology. Included stage III with T4 and/or N2/3 NSCLC and 75% underwent surgery with 29% pCR, 42.2% MPR, mEFS 52.6m. Impressive to note that all N3 achieved ypN0.